J. Titus et al., 2015 - Google Patents
Phosphodiesterase inhibitors as therapeutics for traumatic brain injuryJ. Titus et al., 2015
View PDF- Document ID
- 1282536276733459860
- Author
- J. Titus D
- A. Oliva A
- M. Wilson N
- M. Atkins C
- Publication year
- Publication venue
- Current pharmaceutical design
External Links
Snippet
Developing therapeutics for traumatic brain injury remains a challenge for all stages of recovery. The pathological features of traumatic brain injury are diverse, and it remains an obstacle to be able to target the wide range of pathologies that vary between traumatic brain …
- 208000005765 Traumatic Brain Injury 0 title abstract description 168
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| J Titus et al. | Phosphodiesterase inhibitors as therapeutics for traumatic brain injury | |
| Nabavi et al. | Phosphodiesterase inhibitors say NO to Alzheimer's disease | |
| Omori et al. | Overview of PDEs and their regulation | |
| Bender et al. | Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use | |
| O'Hare et al. | Differential roles of nuclear and cytoplasmic cyclin-dependent kinase 5 in apoptotic and excitotoxic neuronal death | |
| Lugnier | Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents | |
| Bollen et al. | Phosphodiesterases in neurodegenerative disorders | |
| Tönges et al. | ROCKing regeneration: Rho kinase inhibition as molecular target for neurorestoration | |
| RU2303259C2 (en) | Therapeutic application of selective inhibitors pde10 | |
| Rashidian et al. | Cell cycle machinery and stroke | |
| Cheng et al. | Cyclic nucleotide phosphodiesterase (PDE) inhibitors: novel therapeutic agents for progressive renal disease | |
| EP1250923A2 (en) | Use of selective PDE10 inhibitors for the treatment of central nervous system disorders | |
| Zhang et al. | Ten-eleven translocation 1 mediated-DNA hydroxymethylation is required for myelination and remyelination in the mouse brain | |
| P Kelly | Does phosphodiesterase 11A (PDE11A) hold promise as a future therapeutic target? | |
| Wang et al. | Phosphodiesterase: an interface connecting cognitive deficits to neuropsychiatric and neurodegenerative diseases | |
| Oliva Jr et al. | Phosphodiesterase isoform‐specific expression induced by traumatic brain injury | |
| D Ramirez et al. | Regulation of dopamine signaling in the striatum by phosphodiesterase inhibitors: novel therapeutics to treat neurological and psychiatric disorders | |
| Sheng et al. | Inhibition of phosphodiesterase: A novel therapeutic target for the treatment of mild cognitive impairment and Alzheimer’s disease | |
| Saraswat et al. | Overcoming the inhibitory microenvironment surrounding oligodendrocyte progenitor cells following experimental demyelination | |
| Al-Nema et al. | Phosphodiesterase as a target for cognition enhancement in schizophrenia | |
| Timsit et al. | Cerebral ischemia, cell cycle elements and Cdk5 | |
| Wen et al. | Role of phosphodiesterase 4-mediated cyclic AMP signaling in pharmacotherapy for substance dependence | |
| US20030018047A1 (en) | Therapeutic use of selective PDE10 inhibitors | |
| Farooq et al. | GluA2 AMPA glutamate receptor subunit exhibits codon 607 Q/R RNA editing in the lens | |
| Bales et al. | Phosphodiesterase inhibition to target the synaptic dysfunction in Alzheimer’s disease |